Overview

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Status:
Completed
Trial end date:
2020-01-30
Target enrollment:
Participant gender:
Summary
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
Phase:
Phase 4
Details
Lead Sponsor:
Neurocrine Biosciences
Treatments:
Tetrabenazine